:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/arc-anglerfish-arc2-prod-gmg.s3.amazonaws.com/public/72ZFLTMH5BBN3AVNHRWKIDVWLU.jpg)
Cannabis-derived, FDA-approved drug one step closer to patients with rare epilepsy disorders
Read full article: Cannabis-derived, FDA-approved drug one step closer to patients with rare epilepsy disordersSAN ANTONIO – The Drug Enforcement Administration has moved U.S. Food and Drug Administration-approved drugs containing cannibidiol, or CBD, to Schedule V of the Controlled Substances Act. The order places drugs that are FDA-approved and contain no more than 0.1 percent of tetrahydrocannabinol, or THC — the compound in cannabis that gives the user euphoric effects — in Schedule V, the DEA said. Drugs in the Schedule V category include substances containing limited quantities of certain narcotics. The FDA approved the drug Epidiolex, an oral solution that contains CBD, for medical use in the United States to treat two rare forms of epilepsy for patients 2 years or older. Currently, the state’s Compassionate Use Act allows for some qualifying epilepsy patients to access treatment with no more than 0.5 percent THC.